Press releases View full list

March 17, 2015

Invitae to Present Seven Posters Highlighting New Data on the Use of Next-Generation Sequencing for Multi-Gene Panels at the 2015 American College of Medical Genetics Annual Clinical Genetics Meeting

SAN FRANCISCO--(BUSINESS WIRE)-- Invitae Corporation (NYSE:NVTA), a genetic information company, today announced it will be presenting seven posters at the 2015 American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting in Salt Lake City.

The titles and schedule of the poster presentations are as follows:

Poster Session 1: Thursday, March 26, 10:30 a.m.12:00 p.m. MT

  • Poster #105: Next-Generation Panel vs. Traditional BRCA1/2 Testing: Challenging Variants, Classification Under the Draft ACMG ISV Guidelines and Potential Actionability of Findings
  • Poster #139: Expanding the Clinical Spectrum of Mosaic Mutations in TP53 Identified by Next-Generation Sequencing: A Retrospective Analysis
  • Poster #247: Early Onset Charcot-Marie-Tooth Disease with Diaphragmatic Weakness: a Case Report of an Autosomal Recessive MFN2 Compound Heterozygote
  • Poster #383: Discovery and Clinical Interpretation of a SMAD4 Retrotransposon Using Next-Generation Sequencing
  • Poster #415: A Weighted, Score-Based Variant Classification System Based on the 2014 Draft ACMG Guidelines
  • Poster #577: What Do We Do With VUS?: Genetics Professionals' Attitudes Toward Reporting of Variants of Uncertain Significance

Poster Session 2: Friday, March 27, 10:30 a.m.12:00 p.m. MT

  • Poster #118: An Opportunity or a Dilemma? Customizable Panel Tests and Clinician Ordering Behavior

For more detailed information, please visit http://www.acmgmeeting.net/acmg2015/public/mainhall.aspx

About Invitae

Invitae’s (NYSE: NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Currently focused on hereditary cancers, Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time and lower price than many single-gene tests today. The company currently provides a single diagnostic test comprising over 200 genes for a variety of genetic conditions associated primarily with cancer, but also covering cardiology, hematology, neurology and pediatrics.

Source: Invitae Corporation

Invitae Corporation

Katherine Stueland, 415-254-1233

pr@invitae.com

NYSE: NVTA 21.79 +0.11 +0.51% Volume: 1,308,192 20 minute delay September 16, 2019

Investor Toolkit

Feature Presentation

Email Alerts

Sign up to receive Invitae financial information by email.
Email Address: *
I'D LIKE TO RECEIVE EMAILS ABOUT: *




 
Enter the code shown above.

Investor Contact

1400 16th St.
San Francisco, CA, 94103
Email: ir@invitae.com